![Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib](https://oncodaily.com/pub/uploads/2024/07/4c3300ddc2a848a5b93f91877ebf2561.jpg)
Photo from Day One Biopharmaceuticals/LinkedIn
Jul 27, 2024, 22:01
Day One Biopharmaceuticals announces a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib
Day One Biopharmaceuticals shared a post on LinkedIn:
”We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more.”
Jul 27, 2024, 19:56